Evidence map›Paper›PMID 23935864›Full record

ArticlePloS one2013

Protein profiling in hepatocellular carcinoma by label-free quantitative proteomics in two west African populations.

Haddy K S Fye, Cynthia Wright-Drakesmith, Holger B Kramer, Suzi Camey, Andre Nogueira da Costa, Adam Jeng, Alasana Bah, Gregory D Kirk, Mohamed I F Sharif, Nimzing G Ladep and 5 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Proteome Analyses of Hepatocellular Carcinoma.Journal of clinical and translational hepatology · 2014
    Review
  12. Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

15 authors at 7 institutions in 6 countries.

Haddy K S FyeNuffield Department of Medicine, Henry Wellcome Building for Molecular Physiology - University of Oxford, Oxford, Oxfordshire, United Kingdom.
Cynthia Wright-Drakesmith
Holger B Kramer
Suzi Camey
Andre Nogueira da Costa
Adam Jeng
Alasana Bah
Gregory D Kirk
Mohamed I F Sharif
Nimzing G Ladep
Edith Okeke
Pierre Hainaut
Simon D Taylor-Robinson
Benedikt M Kessler
Maimuna E Mendy
Centre International de Recherche sur le Cancer · FRImperial College London · GBMRC Unit the Gambia · GMUniversity of Oxford · GBJohns Hopkins University · USJos University Teaching Hospital · NGUniversidade Federal do Rio Grande do Sul · BR

Funding

Medical Research CouncilNCI NIH HHS N02CP40521Wellcome Trust 084655
6 · The paper itself

Abstract

backgroundHepatocellular Carcinoma is the third most common cause of cancer related death worldwide, often diagnosed by measuring serum AFP; a poor performance stand-alone biomarker. With the aim of improving on this, our study focuses on plasma proteins identified by Mass Spectrometry in order to investigate and validate differences seen in the respective proteomes of controls and subjects with LC and HCC.

methodsMass Spectrometry analysis using liquid chromatography electro spray ionization quadrupole time-of-flight was conducted on 339 subjects using a pooled expression profiling approach. ELISA assays were performed on four significantly differentially expressed proteins to validate their expression profiles in subjects from the Gambia and a pilot group from Nigeria. Results from this were collated for statistical multiplexing using logistic regression analysis.

resultsTwenty-six proteins were identified as differentially expressed between the three subject groups. Direct measurements of four; hemopexin, alpha-1-antitrypsin, apolipoprotein A1 and complement component 3 confirmed their change in abundance in LC and HCC versus control patients. These trends were independently replicated in the pilot validation subjects from Nigeria. The statistical multiplexing of these proteins demonstrated performance comparable to or greater than ALT in identifying liver cirrhosis or carcinogenesis. This exercise also proposed preliminary cut offs with achievable sensitivity, specificity and AUC statistics greater than reported AFP averages.

conclusionsThe validated changes of expression in these proteins have the potential for development into high-performance tests usable in the diagnosis and or monitoring of HCC and LC patients. The identification of sustained expression trends strengthens the suggestion of these four proteins as worthy candidates for further investigation in the context of liver disease. The statistical combinations also provide a novel inroad of analyses able to propose definitive cut-offs and combinations for evaluation of performance.

Indexed as

ProteomeProteomicsAdultAfrica, Westernalpha 1-AntitrypsinApolipoprotein A-IBiomarkers, TumorCarcinoma, HepatocellularCase-Control StudiesComplement C3Enzyme-Linked Immunosorbent AssayFemaleHemopexinHepatitis B, ChronicHumansLiver Cirrhosisalpha 1-AntitrypsinApolipoprotein A-IBiomarkers, TumorComplement C3HemopexinProteome

Identifiers

PMID23935864
PMCPMC3728326
OpenAlexW2057205471

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.